| Literature DB >> 30765947 |
Lorenzo Ridola1, Silvia Nardelli2, Stefania Gioia2, Oliviero Riggio2.
Abstract
The design of clinical trials on Hepatic Encephalopathy (HE) is not an easy task, in fact there are several issues related to the performance of clinical trials in HE that have impeded progress in the field, mainly because most of the studies on HE therapy were performed before the era of rigorous Randomized Controlled Trials (RCTs). In this review we discuss the major problems affecting previously published trials on HE treatments aiming to provide evidences, suggestions and indications to prepare well designed RCTs in three different settings: (1) management of hospitalized patients with episodic HE; (2) secondary prophylaxis in patients following an episode of HE; and (3) management of minimal/covert HE.Entities:
Keywords: BCAA, Branched Chain Amino Acids; HE, Hepatic Encephalopathy; RCTs, Randomized Controlled Trials; hepatic encephalopathy; minimal hepatic encephalopathy; randomized controlled trial
Year: 2018 PMID: 30765947 PMCID: PMC6363957 DOI: 10.1016/j.jceh.2018.02.007
Source DB: PubMed Journal: J Clin Exp Hepatol ISSN: 0973-6883